Dexycu may receive extension of pass-through payment status
Click Here to Manage Email Alerts
EyePoint Pharmaceuticals anticipates a 9-month extension to Dexycu’s pass-through payment status, according to a press release.
The current pass-through payment status for Dexycu (dexamethasone intraocular suspension 9%) would expire on March 31, 2022, without an extension, the release said.
“We are extremely pleased that the CMS has indicated it intends to provide additional pass-through time, subject to public comment, allowing for another 9 months of pass-through status for important innovative products such as Dexycu,” Nancy Lurker, CEO of EyePoint Pharmaceuticals, said in the release.
CMS released the 2022 draft Hospital Outpatient Prospective Payment System rule on July 19, with a final rule expected to come in November, the release said.
Read more about
Click Here to Manage Email Alerts